Literature DB >> 6195699

Immunoreactive pancreatic secretory trypsin inhibitor in gynecological diseases.

A Murata, M Ogawa, K Matsuda, N Matsuura, G Kosaki, M Inoue, G Ueda, K Kurachi.   

Abstract

Serum immunoreactive pancreatic secretory trypsin inhibitor in 45 patients with various gynecological diseases was measured by a radioimmunoassay. In normal serum of healthy individuals, the concentration was 11.7 +/- 2.3 ng/ml (mean +/- SD). Elevated levels (above control mean plus 3 S.D.) were observed in sera of 5 patients (50%) with ovarian cancer, and serum of one patient (4.7%) with uterine cancer. Only one tumor extract of ovarian cancer contained a significant level of immunoreactive PSTI. PSTI-containing mucin was detected in a mucin-producing ovarian adenocarcinoma.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6195699

Source DB:  PubMed          Journal:  Res Commun Chem Pathol Pharmacol        ISSN: 0034-5164


  3 in total

1.  Reaction of a tumour-associated trypsin inhibitor with serine proteinases associated with coagulation and tumour invasion.

Authors:  U Turpeinen; E Koivunen; U H Stenman
Journal:  Biochem J       Date:  1988-09-15       Impact factor: 3.857

2.  Varying occurrence of gastroduodenal immunoreactive pancreatic secretory trypsin inhibitor.

Authors:  M Bohe; C G Lindström; K Ohlsson
Journal:  J Clin Pathol       Date:  1987-11       Impact factor: 3.411

3.  Tumour-associated trypsin inhibitor, TATI, in patients with pancreatic cancer, pancreatitis and benign biliary diseases.

Authors:  C Haglund; M L Huhtala; H Halila; S Nordling; P J Roberts; T M Scheinin; U H Stenman
Journal:  Br J Cancer       Date:  1986-08       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.